Ironically, the first person to be diagnosed with what is now Alzheimer’s disease was missing its major risk factor. When she first began showing symptoms of dementia in 1901, Auguste Deter was not particularly old. Despite Deter’s case, aging is the largest risk factor for developing Alzheimer’s, by a large margin. But “geroscience has not been translated into drugs for Alzheimer’s disease,” Howard Fillit, Alzheimer’s Drug Discovery Foundation co-founder and chief scientific officer, told BioWorld. “We’re just starting to see that cross-fertilization now.” This first article of a three-part BioWorld series on Alzheimer’s disease looks at how a group of researchers, as well as some startups, are trying to approach Alzheimer’s via an aging lens.
The research not only unveils a potential therapy to address age-related liver pathologies but also underscores the importance of bone marrow function in blood cell production. TheHealthSite.com
The number one reason consumers take dietary supplements is to bolster their immunity, according to dsm-firmenich. In fact, 66% of supplement users say they plan to address immune health over the next 12 months.
Gencor’s branded PEA can now be found in the beauty category for its ability to aid in a healthy inflammatory response and protect from oxidative stress-induced damage.
With a new study in healthy humans supporting the safety and efficacy of TSI’s Hobamine-branded 2-Hydroxybenzylamine (2-HOBA), the company is bullish about its potential to support a healthier immuno-inflammatory system.